Health
19 Oct 2026
Cyclin E1 predicts survival with azenosertib
In a Phase II study, Cyclin E1‑positive patients lived a median 15.8 months, compared with 7.5 months for Cyclin E1‑negative.
Read moreTopic
#Cyclin E1
1 story
Topic
1 story